Triptorelin Pamoate (Trelstar®)

Common name: Triptorelin Pamoate
Brand name: Trelstar®
 

What is Triptorelin Pamoate?

Triptorelin is used in the palliative treatment of hormone dependent advanced prostate cancer. It works by reducing the amount testosterone in the blood.
 

How is Triptorelin Pamoate administered?

Triptorelin Pamoate is administered by intramuscular injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received triptorelin pamoate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast enlargement
  • Constipation
  • Diarrhea
  • Difficulty sleeping
  • Fatigue / weakness
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea
  • Reduced libido (low sex drive)

 
Is Triptorelin Pamoate covered in my province or territory?

Triptorelin pamoate is covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Ontario
  • Quebec
  • Prince Edward Island
  • Yukon
Triptorelin pamoate is not covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Saskatchewan



 
Last Reviewed: November 2013

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive